With an upside potential of 77%, Tigo Energy, Inc. (NASDAQ:TYGO) is among the 11 Most Promising Renewable Energy Stocks Right Now. Tigo Energy, Inc. (NASDAQ:TYGO) received a higher analyst target on May 7 when Roth Capital raised its price objective to $7 from $5 while mai
With an upside potential of 42.5%, SUNation Energy Inc. (NASDAQ:SUNE) is among the 11 Most Promising Renewable Energy Stocks Right Now. On April 17, SUNation Energy Inc. (NASDAQ:SUNE) announced that it entered into a strategic financing agreement with Participate Energy to
With an upside potential of 34.59%, Stem, Inc. (NYSE:STEM) is among the 11 Most Promising Renewable Energy Stocks Right Now. Stem, Inc. (NYSE:STEM) announced on May 13 that it has entered into a new services agreement with Bluesphere Ventures to support a portfolio of stan
With an upside potential of 31.60%, Sunrun Inc. (NASDAQ:RUN) is among the 11 Most Promising Renewable Energy Stocks Right Now. Sunrun Inc. (NASDAQ:RUN) received updated analyst coverage on May 8 when Deutsche Bank analyst Corinne Blanchard raised the firm’s price target to
A fund reduced its stake in MAZE by 70,503 shares, trimming holdings to 99,850 shares worth $2.98 million. HighVista Strategies sold 70,503 shares of Maze Therapeutics (NASDAQ:MAZE) in Q1 2026, valued at approximately $3.11 million based on the quarter’s average closing pr
The stock market is flashing too many warning signs to ignore, according to BTIG technical strategist Jonathan Krinsky, though he sees a couple of areas that could encourage the bulls. Krinsky noted that the SPDR S&P 500 (SPY) had The stock market is flashing too many warn
HighVista Strategies added 96,218 shares of Tyra Biosciences, now valued at $3.11 million, as the stock outperformed the S&P 500 by 250 percentage points. HighVista Strategies increased its position in Tyra Biosciences (NASDAQ:TYRA) by 96,218 shares, valued at $3.11 millio
High-net-worth individuals employ advanced strategies to offset capital gains taxes despite strong market performance. Wealthy investors and advisors are ramping up tax-loss harvesting techniques to generate losses in portfolios that continue to appreciate. The approach ai
A fund reduced its Viridian Therapeutics holdings by 238,243 shares, cutting exposure before a June 30 FDA catalyst. HighVista Strategies sold 238,243 shares of Viridian Therapeutics (VRDN) in Q1 2026, valued at approximately $7.08 million based on average pricing. The mov
Palantir reports $687 million in U.S. government revenue for Q1 2026, up 84% year-over-year, and lifts full-year guidance to 71% growth. Palantir Technologies (NASDAQ: PLTR) posted $687 million in U.S. government revenue for the first quarter of 2026, an 84% year-over-year
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.